Replies to post #13997 on Sorrento Therapeutics Inc (SRNE)

[1776club]

OK, all good. How far along are these programs and when will these programs be approved by the FDA or by another country? When will these programs bring in significant revenue? At the current burn rate, we have until the end of the first quarter of 2023 to bring in approximately $180 million a quarter.
PD-L1 is at Phase 2 January 2024 /July 2024

DAR-T /CAR-T I do not see anything close to the finish line and one has to ask are the PhD's and others leaving as programs are not currently funded.

https://www.learn4good.com/jobs/san-diego/california/research_and_development/1434327943/e/

I do not see anything, except Mpro which seems to take 1 to 2 years after P3 for the FDA to approve, but then there is China... maybe their need is so great approval will come quickly.

Supposedly P3 was completed in China, I believe, with Abivertinib so could approval be on the way?

One large question regarding SCILEX is where is the NDA for SEMDEXA? Been waiting 7 months to see Sorrento apply for it as they need cashflow and the results were very good. Sorrento is applying for an NDA at a P2 for ABIVERTINIB, but their P3 was rejected due to lack of broad diversity of the population from China, but not from a completed P3 from SEMDEXA? Something is very wrong.

SOFUSA? Nothing is out of P1 until 2024.

Not all Dr. Ji's fault as the economy shrunk his $2 Billion + revenue from stock sales to millions, but he should have pulled back much sooner on expenditures. He needs to reduce expenditures significantly, but he is adding very expensive property in a short while.